Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Ovarian cancer stem cells: still an elusive entity?

Lupia M, Cavallaro U.

Mol Cancer. 2017 Mar 20;16(1):64. doi: 10.1186/s12943-017-0638-3. Review.

2.

Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.

Lee HH, Bellat V, Law B.

PLoS One. 2017 Feb 14;12(2):e0171044. doi: 10.1371/journal.pone.0171044. eCollection 2017 Feb 14.

3.

HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features.

Argaw-Denboba A, Balestrieri E, Serafino A, Cipriani C, Bucci I, Sorrentino R, Sciamanna I, Gambacurta A, Sinibaldi-Vallebona P, Matteucci C.

J Exp Clin Cancer Res. 2017 Jan 26;36(1):20. doi: 10.1186/s13046-016-0485-x.

4.

Differential Cytotoxic Potential of Silver Nanoparticles in Human Ovarian Cancer Cells and Ovarian Cancer Stem Cells.

Choi YJ, Park JH, Han JW, Kim E, Jae-Wook O, Lee SY, Kim JH, Gurunathan S.

Int J Mol Sci. 2016 Dec 12;17(12). pii: E2077.

5.

Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma.

Khalil MA, Hraběta J, Groh T, Procházka P, Doktorová H, Eckschlager T.

PLoS One. 2016 Sep 14;11(9):e0162916. doi: 10.1371/journal.pone.0162916. eCollection 2016 Sep 14.

6.

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.

Kim MK, Caplen N, Chakka S, Hernandez L, House C, Pongas G, Jordan E, Annunziata CM.

BMC Cancer. 2016 Aug 24;16:678. doi: 10.1186/s12885-016-2675-5.

7.

Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy.

Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M.

Stem Cells Int. 2016;2016:1740936. doi: 10.1155/2016/1740936. Epub 2016 Jun 21. Review.

8.

Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Yan B, Yin F, Wang QI, Zhang W, Li LI.

Oncol Lett. 2016 Jul;12(1):157-166. Epub 2016 May 18.

9.

Biological characteristics of side population cells in a self-established human ovarian cancer cell line.

Wei Z, Lv S, Wang Y, Sun M, Chi G, Guo J, Song P, Fu X, Zhang S, Li Y.

Oncol Lett. 2016 Jul;12(1):41-48. Epub 2016 May 13.

10.

Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.

Deng J, Wang L, Chen H, Hao J, Ni J, Chang L, Duan W, Graham P, Li Y.

Oncotarget. 2016 Aug 23;7(34):55771-55788. doi: 10.18632/oncotarget.9908. Review.

11.

Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.

Wu X, Wu F, Xu D, Zhang T.

J Neurooncol. 2016 Apr;127(2):221-32. doi: 10.1007/s11060-015-2039-z. Epub 2016 Jan 12. Erratum in: J Neurooncol. 2016 Apr;127(2):233.

12.

Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2.

Choi YJ, Ingram PN, Yang K, Coffman L, Iyengar M, Bai S, Thomas DG, Yoon E, Buckanovich RJ.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E6882-8. doi: 10.1073/pnas.1507899112. Epub 2015 Nov 30.

13.

Circulating cancer stem cells: the importance to select.

Yang MH, Imrali A, Heeschen C.

Chin J Cancer Res. 2015 Oct;27(5):437-49. doi: 10.3978/j.issn.1000-9604.2015.04.08. Review.

14.

Reduced graphene oxide-silver nanoparticle nanocomposite: a potential anticancer nanotherapy.

Gurunathan S, Han JW, Park JH, Kim E, Choi YJ, Kwon DN, Kim JH.

Int J Nanomedicine. 2015 Oct 5;10:6257-76. doi: 10.2147/IJN.S92449. eCollection 2015 Oct 5.

15.

Targeting cancer stem cells by using the nanoparticles.

Hong IS, Jang GB, Lee HY, Nam JS.

Int J Nanomedicine. 2015 Sep 10;10(Spec Iss):251-60. doi: 10.2147/IJN.S88310. eCollection 2015 Sep 10. Review.

16.

Chemotherapy targeting cancer stem cells.

Liu H, Lv L, Yang K.

Am J Cancer Res. 2015 Feb 15;5(3):880-93. eCollection 2015 Feb 15. Review.

17.

Ovarian stem cells: From basic to clinical applications.

Ozakpinar OB, Maurer AM, Ozsavci D.

World J Stem Cells. 2015 May 26;7(4):757-68. doi: 10.4252/wjsc.v7.i4.757. Review.

18.

Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

Ayub TH, Keyver-Paik MD, Debald M, Rostamzadeh B, Thiesler T, Schröder L, Barchet W, Abramian A, Kaiser C, Kristiansen G, Kuhn W, Kübler K.

Oncotarget. 2015 Jun 30;6(18):16437-48.

19.

Oncolytic virotherapy for ovarian cancer.

Li S, Tong J, Rahman MM, Shepherd TG, McFadden G.

Oncolytic Virother. 2012 Aug;1:1-21.

20.

CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.

Burgos-Ojeda D, Wu R, McLean K, Chen YC, Talpaz M, Yoon E, Cho KR, Buckanovich RJ.

Mol Cancer Ther. 2015 Jul;14(7):1717-27. doi: 10.1158/1535-7163.MCT-14-0607. Epub 2015 May 12.

Supplemental Content

Support Center